272 related articles for article (PubMed ID: 18705639)
1. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study.
Toutouzas K; Patsa C; Tsiamis E; Tsioufis C; Spanos A; Stefanadi E; Tentolouris C; Stefanadis C
J Interv Cardiol; 2008 Oct; 21(5):388-94. PubMed ID: 18705639
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
5. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome after management of unprotected left main in-stent restenosis after bare metal or drug-eluting stents.
Chen SL; Xu B; Mintz G; Ye F; Zhang JJ; Kan J; Sun XW; Zhang AP; Chen JG; Qian J; Kwan TW
Chin Med J (Engl); 2010 Apr; 123(7):794-9. PubMed ID: 20497666
[TBL] [Abstract][Full Text] [Related]
9. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
10. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
11. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
[TBL] [Abstract][Full Text] [Related]
12. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes following drug-eluting versus bare metal stent implantation for lesion subsets excluded from pivotal clinical trials: findings from the GHOST Study (Guthrie Health System Off-Label StenT Study).
Harjai KJ; Orshaw P; Shenoy C; Acharji S; Sporn D; Aboufares A; Stapleton D
J Interv Cardiol; 2008 Aug; 21(4):315-24. PubMed ID: 18754967
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
Alfonso F; Pérez-Vizcayno MJ; Hernández R; Bethencourt A; Martí V; López-Mínguez JR; Angel J; Iñiguez A; Morís C; Cequier A; Sabaté M; Escaned J; Jiménez-Quevedo P; Bañuelos C; Suárez A; Macaya C;
J Am Coll Cardiol; 2008 Nov; 52(20):1621-7. PubMed ID: 18992651
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-eluting stents for the treatment of bare-metal in-stent restenosis: long-term clinical follow up.
Sheiban I; Chiribiri A; Beninati S; Moretti C; Omede P; Sciuto F; Marra WG; Biondi-Zoccai G; Bollati M; Gambino A; Trevi GP
J Invasive Cardiol; 2007 Apr; 19(4):174-80. PubMed ID: 17404403
[TBL] [Abstract][Full Text] [Related]
16. ISR II study: a long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions.
Commeau P; Barragan PT; Roquebert PO; Siméoni JB
Catheter Cardiovasc Interv; 2005 Oct; 66(2):158-62. PubMed ID: 16158397
[TBL] [Abstract][Full Text] [Related]
17. Coexistent in-stent restenosis, late incomplete stent apposition and mural thrombus in a zotarolimus-eluting stent.
Zhang F; Qian J; Ge J
J Invasive Cardiol; 2008 Aug; 20(8):423-5. PubMed ID: 18688068
[TBL] [Abstract][Full Text] [Related]
18. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
[TBL] [Abstract][Full Text] [Related]
19. Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
Liistro F; Fineschi M; Grotti S; Angioli P; Carrera A; Ducci K; Gori T; Falsini G; Pierli C; Bolognese L
J Am Coll Cardiol; 2010 Feb; 55(7):613-6. PubMed ID: 20170784
[TBL] [Abstract][Full Text] [Related]
20. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]